Rethinking Life Sciences Commercialization
for 2026: What’s Working, What’s Not and What’s Next
We asked 140 life sciences leaders what drives or derails commercialization.
They cited fragmented data, limited visibility, unclear ownership, and the challenge of keeping pace with AI and market changes. Big pharma and emerging biopharma take different paths, but each offers lessons from which the other can learn.
On November 13, 2025, we shared our findings and real-world lessons from our panel of industry and Beghou experts during the webinar.
We discussed:
- Success drivers and barriers: How teams are “making it work with less” and the unintended pitfalls and learnings across commercial operations, data, access, and engagement
- Timing and planning learnings: How early is "early enough" and how to stay agile once plans are in motion
- “What works” across company sizes: What large and emerging biopharma can learn from each other’s playbooks
- Real-world case studies: Case studies and practical takeaways for building sustainable commercial success
Here are the webinar slides and recording:
Note: Commercialization That Works is Beghou’s flagship research, distilling what’s driving effective commercialization in life sciences and the flip side – what to avoid. Our initial results were compiled from proprietary analysis of 21 panel-based and 1:1 interviews and a 120-person survey with life sciences commercialization leaders based in the United States.
